Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Diagnostic Performance of Salivary Interleukin-8 and Serum Interleukin-6 for Oral Potentially Malignant Disorders: Effect Modification by Smoking Status - A Cross-Sectional Study

NCT07915570 is registered in ClinicalTrials.gov with British University In Egypt as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07915570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Diagnostic Performance of Salivary Interleukin-8 and Serum Interleukin-6 for Oral Potentially Malignant Disorders: Effect Modification by Smoking Status - A Cross-Sectional Study
Lead sponsor
British University In Egypt
Phase
Observational
Overall status
Recruiting
Start date
October 1, 2026
Completion date
January 30, 2027
Enrollment
250 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

oral leukoplakia, oral lichen planus, oral potentially malignant disorders, oral squamous cell carcinoma, smoking

Arms

As registered; 5 arms.

  • Healthy Controls - Never-Smokers Salivary IL-8 and Serum IL-6 Measurement

    Adults with clinically healthy oral mucosa and no current or previous oral potentially malignant disorder or oral cancer, who have never smoked (n = 50). Single-visit collection of unstimulated whole saliva (IL-8) and serum (IL-6), with clinical, periodontal and tobacco-use assessment.

  • Healthy Controls - Current Smokers Salivary IL-8 and Serum IL-6 Measurement

    Adults with clinically healthy oral mucosa and no current or previous oral potentially malignant disorder or oral cancer, who are current smokers (n = 50). Single-visit collection of unstimulated whole saliva (IL-8) and serum (IL-6), with clinical, periodontal and tobacco-use assessment.

  • OPMD - Never-Smokers Salivary IL-8 and Serum IL-6 Measurement

    Adults who have never smoked, with a histopathologically confirmed oral potentially malignant disorder (oral lichen planus or oral leukoplakia) and no definitive treatment of the lesion before sample collection (n = 50). Single-visit collection of unstimulated whole saliva (IL-8) and serum (IL-6), with clinical, histopathological, periodontal and tobacco-use assessment.

  • OPMD - Current Smokers Salivary IL-8 and Serum IL-6 Measurement

    Adults who are current smokers, with a histopathologically confirmed oral potentially malignant disorder (oral lichen planus or oral leukoplakia) and no definitive treatment of the lesion before sample collection (n = 50). Single-visit collection of unstimulated whole saliva (IL-8) and serum (IL-6), with clinical, histopathological, periodontal and tobacco-use assessment.

  • OSCC - Current Smokers (Exploratory) Salivary IL-8 and Serum IL-6 Measurement

    Adults who are current smokers, with histopathologically confirmed oral squamous cell carcinoma (n = 50). Exploratory cohort compared with current-smoking OPMD patients; not included in the primary healthy control versus OPMD comparisons. Single-visit collection of unstimulated whole saliva (IL-8) and serum (IL-6), with clinical, histopathological (tumor grade), periodontal and tobacco-use assessment.

Primary endpoints

Registered primary outcome measures; 2 primary.

  • Salivary IL-8 Concentration At enrollment (single visit, before any definitive lesion treatment)

    Salivary interleukin-8 (IL-8) concentration, measured using an enzyme-linked immunosorbent assay (ELISA) and expressed in pg/mL. Concentrations are compared between healthy controls and participants with oral potentially malignant disorders (OPMDs), with analyses stratified by smoking status where applicable.

  • Serum IL-6 Concentration At enrollment (single visit, before any definitive lesion treatment)

    Serum interleukin-6 (IL-6) concentration, measured using an ELISA and expressed in pg/mL. Concentrations are compared between healthy controls and participants with OPMDs, with analyses stratified by smoking status where applicable.

Lead sponsor's other trials

British University In Egypt, most recent start first.

Similar trials

Same condition (Leukoplakia, Oral) and phase, most recent start first.